Creative Planning Has $12.72 Million Stake in Sanofi (NASDAQ:SNY)

Creative Planning grew its stake in Sanofi (NASDAQ:SNY) by 18.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 220,763 shares of the company’s stock after buying an additional 33,728 shares during the period. Creative Planning’s holdings in Sanofi were worth $12,723,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. POM Investment Strategies LLC acquired a new stake in Sanofi in the 2nd quarter worth approximately $25,000. Register Financial Advisors LLC bought a new stake in shares of Sanofi during the 1st quarter worth $29,000. Larson Financial Group LLC grew its stake in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the last quarter. Palisade Asset Management LLC bought a new position in Sanofi in the 1st quarter worth $31,000. Finally, Arrow Financial Corp acquired a new position in Sanofi during the 2nd quarter worth $35,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 2.3 %

SNY opened at $53.66 on Tuesday. The company has a market capitalization of $136.16 billion, a P/E ratio of 29.16, a P/E/G ratio of 1.57 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm’s fifty day moving average price is $56.13 and its two-hundred day moving average price is $51.62. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 EPS. On average, analysts anticipate that Sanofi will post 4.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SNY. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.